Midatech Pharma (AIM:MTPH, Nasdaq:MTP), the international specialty pharmaceutical company focused on developing and commercialising products for rare diseases in oncology and immunotherapy, today announces interim data from the ‘first-in-human’ study of MTD201 Q-Octreotide, a sustained-release treatment for carcinoid cancer and acromegaly. As quoted in the press release: The double-blind exploratory study compared tolerability, pharmacokinetics and … Continued